PATENT CLAIM ANALYSIS

Application Number: 15910945
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "142100"]

Abstract:
Disclosed herein are methods of treating pain using RANK/RANKL antagonists.

Claim (Index 24):
The method of  claim 13 , wherein the antibody CDR sequences have at least about 90% sequence identity to the CDR sequences of denosumab.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 90.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15269799', '14495732', '14812989', '14952724', '15182378']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7786893594871572
- 35 USC 102 Novelty (BERT): 0.5512763100040167
- Combined Prediction Score: 0.7559480545388432
- Mean Citation Score: 336.6952520000001
- Max Citation Score: 394.25766
- Similarity Product: 243.3536236326277

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test